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We are aware of the substantial interest shown in the recent publication in JAMA 
internal medicine by Kitahara et al1. This retrospective analysis of data from the large 
multicentre Cooperative Thyrotoxicosis Therapy Follow-up study (CTTFUS) suggests 
a modest increase in potential risk of death from cancer in people who receive 
radioiodine therapy for hyperthyroidism. These findings have obviously raised 
considerable concern as radioiodine is one of the key treatment options in 
hyperthyroidism, particularly in those who relapse or have disease that is difficult to 
control. Experience with radioiodine is longstanding and it is a widely used treatment 
modality for hyperthyroidism. The conclusion in this paper that “in RAI-treated patients 
with hyperthyroidism, greater organ-absorbed doses appeared to be modestly 
positively associated with risk of death from solid cancer, including breast cancer” has 
naturally caused anxiety for both patients and clinicians. Whilst the work in the study 
is innovative and detailed, the Society for Endocrinology (SFE) and the British Thyroid 
Association (BTA) are concerned that the conclusion will need to be interpreted 
cautiously for the following reasons. 
1) There was no control cohort with hyperthyroidism in this study. This is a 
substantial limitation of the study. It is not clear why patients with hyperthyroidism who 
did not receive radioiodine were not used as controls since this data is available in the 
CTTFUS cohort. The lack of a hyperthyroidism control group makes it difficult to 
ascertain if the increase in cancer risk is a consequence of hyperthyroidism and poor 
disease control or of radioiodine per se. This is important, as a previous analyses of 
the CTTFUS dataset which included a control group did not find increased risk of 
cancer mortality from radioiodine2. Furthermore a further analysis of the CTTFUS 
dataset by two of the study co-authors has shown no excess cancer mortality 
attributable to radioiodine whereas an increased risk of solid cancer deaths was 
observed in hyperthyroid patients who were not treated with radioiodine or surgery3. 
This discrepancy with findings of the original study is a cause for concern and calls for 
a more detailed evaluation of cancer risks in the entire CTTFUS cohort. 
2) The model used to calculate the absorbed radioiodine dose is novel but not 
validated. A complex mathematical model has been used to estimate the absorbed 
radioiodine dose, based on a series of assumptions on thyroid gland weight and 
radioiodine uptake in a small preliminary sample of patients. These assumptions leave 
significant uncertainties in organ dose exposure and whilst impressive, will need to be 
replicated further and validated.  
3) In the analysis, important confounders such as smoking and obesity have not 
been considered. The analysis did not correct for a number of important confounders 
for cancer risk including smoking, obesity, alcohol intake, and biochemical disease 
severity.  This is likely due to the nature of the dataset used, but it remains an important 
limitation which should warrant further caution in the interpretation of data and 
conclusions. 
4) Excess solid cancer risk is not seen following administration of substantially 
higher doses of radioiodine to patients with thyroid cancer. Studies in radioiodine-
treated thyroid cancer patients show development of secondary cancers only when 
doses in excess of 10 GBq are administered and the most commonly observed 
malignancies are haematological cancers such as leukaemia4. A causative role for 
radioiodine in the  study findings thus seems unlikely given that excess risk was only 
observed for solid malignancies, and the administered radioiodine doses were well 
below the expected threshold for cancer risk.  
5) Whilst statistically significant, the magnitude of observed effects in this study 
are modest. The risks observed were marginal, with an estimated relative risk of 1.06, 
95% Confidence Interval, 1.02—1.10, for total solid cancer mortality. Thus, given the 
uncertainties in the radioiodine dose estimates, the potential for unexplored 
confounding influences, and the lack of patient control groups, these marginal risks 
will need to be interpreted with caution. 
Recent observations have shown the importance of achieving good control of 
hyperthyroidism in a timely fashion to improve long-term cardiovascular and mortality 
outcomes5,6. In this context, it would be unfortunate if patients were deprived of the 
option of rapid, effective control of their hyperthyroidism with radioiodine, due to 
concerns of cancer risk. Overall, on the basis that current evidence shows no excess 
cancer risk, it would be reasonable to continue with current approaches to the 
management of hyperthyroidism, whilst further, appropriately controlled studies are 
undertaken. We believe that long term monitoring of outcomes, including cancer 
mortality risk, is essential for patients who have undergone radioiodine therapy . We 
endorse and would actively support efforts to construct large national databases of 
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